1. Diabetes Mellitus (DM)
Q1: What are the diagnostic criteria for Diabetes Mellitus?
* Answer: Diabetes can be diagnosed using any of the following criteria (confirmed on a subsequent day unless clear symptoms exist):
* Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L).
* 2-hour post-prandial glucose ≥ 200 mg/dL (11.1 mmol/L) during an Oral Glucose Tolerance Test (OGTT).
* Hemoglobin A1c (HbA1c) ≥ 6.5%.
* Random plasma glucose ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.
Q2: How do you clinically differentiate between Type 1 and Type 2 Diabetes Mellitus during an initial presentation?
* Answer: Type 1 DM typically presents in younger, leaner individuals with an acute onset of symptoms (polyuria, polydipsia, rapid weight loss) or DKA, caused by autoimmune destruction of beta cells (positive for anti-GAD65 or anti-islet cell antibodies; low C-peptide). Type 2 DM occurs more commonly in older, overweight/obese adults, has an insidious onset, is driven by insulin resistance, and features normal-to-elevated C-peptide levels early in the disease.
Q3: What is the first-line pharmacological treatment for Type 2 DM, and what is its most important renal contraindication?
* Answer: Metformin is the first-line oral agent due to its efficacy, weight neutrality, and cardiovascular safety. It is strictly contraindicated in patients with severe renal impairment, specifically when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73m², due to the increased risk of lactic acidosis.
Q4: Which classes of diabetes medications offer clear cardiovascular and renal benefits?
* Answer: SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) and GLP-1 receptor agonists (e.g., semaglutide, liraglutide) have demonstrated definitive cardiovascular risk reduction and nephroprotective benefits in patients with established atherosclerotic cardiovascular disease or chronic kidney disease.
Q5: What are the primary microvascular and macrovascular complications of chronic diabetes?
* Answer:
* Microvascular: Retinopathy, Nephropathy, and Neuropathy (peripheral and autonomic).
* Macrovascular: Coronary Artery Disease (CAD/MI), Cerebrovascular Disease (stroke/TIA), and Peripheral Arterial Disease (PAD).
2. CVA vs TIA
Q1: What is the fundamental clinical difference between a Cerebrovascular Accident (CVA) and a Transient Ischemic Attack (TIA)?
* Answer: The classic distinction is based on tissue vs. time. A TIA is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction on neuroimaging, typically resolving within 24 hours. A CVA (Stroke) involves permanent neurological deficits backed by evidence of tissue necrosis/infarction on imaging.
Q2: What is the first diagnostic imaging modality that must be performed for a patient presenting with acute stroke symptoms, and why?
* Answer: A non-contrast Head CT scan must be performed immediately. Its primary purpose is not to visualize an acute ischemic stroke (which may not show up for hours), but to immediately rule out intracranial hemorrhage, which dictates entirely different management paths.
Q3: What is the standard therapeutic time window for administering intravenous tissue plasminogen activator (tPA) in acute ischemic stroke?
* Answer: The standard window for intravenous thrombolysis (alteplase/tenecteplase) is within 3 hours of symptom onset, which can be extended up to 4.5 hours in selected patients who meet specific inclusion criteria and lack exclusion risks.
Q4: Name three absolute contraindications to administering tPA in an acute ischemic stroke.
* Answer: Absolute contraindications include:
* Active internal bleeding or acute intracranial hemorrhage on CT.
* History of intracranial hemorrhage, structural cerebral vascular lesion, or intracranial neoplasm.
* Ischemic stroke or severe head trauma within the past 3 months.
* Current severe, uncontrolled hypertension (Systolic > 185 mmHg or Diastolic > 110 mmHg).
Q5: What tool is used to assess the short-term stroke risk after a TIA, and what are its components?
* Answer: The ABCD² score evaluates stroke risk post-TIA. Its components are: Age (≥ 60 years), Blood pressure (≥ 140/90 mmHg), Clinical features (unilateral weakness, speech impairment without weakness), Duration of symptoms (10–59 mins vs. ≥ 60 mins), and Diabetes status.
3. DKA vs HHS
Q1: What are the key laboratory criteria that differentiate Diabetic Ketoacidosis (DKA) from Hyperosmolar Hyperglycemic State (HHS)?
* Answer:
* DKA: Serum glucose usually > 250 mg/dL, arterial pH < 7.3, serum bicarbonate < 18 mEq/L, and positive serum/urine ketones with an elevated anion gap.
* HHS: Serum glucose markedly elevated (often > 600 mg/dL), arterial pH > 7.3, serum bicarbonate > 18 mEq/L, minimal or absent ketonuria/ketonemia, and effective serum osmolality > 320 mOsm/kg.
Q2: What is the initial, most critical step in managing both DKA and HHS?
* Answer: Aggressive intravenous fluid resuscitation with isotonic saline (0.9% NaCl) to restore intravascular volume, improve renal perfusion, and lower counter-regulatory hormone levels. Fluid resuscitation must always precede or run concurrently with insulin therapy.
Q3: At what serum potassium level must insulin administration be delayed in a patient presenting with DKA?
* Answer: If the serum potassium level is below 3.3 mEq/L, insulin therapy must be held. Potassium must be aggressively repleted first because insulin drives potassium intracellularly, which can cause life-threatening hypokalemia, arrhythmias, or cardiovascular collapse.
Q4: What are the criteria used to determine when DKA has resolved so that a patient can transition from IV to subcutaneous insulin?
* Answer: DKA is resolved when the anion gap has closed (typically < 12 mEq/L), blood pH is > 7.3, serum bicarbonate is ≥ 18 mEq/L, and the patient is clinically stable and able to tolerate oral intake.
Q5: Why must blood glucose levels not be lowered too rapidly during the treatment of HHS?
* Answer: Lowering blood glucose and serum osmolality too quickly (more than 75–100 mg/dL per hour) can cause a rapid fluid shift from the extracellular space into the brain cells, posing a severe risk of cerebral edema.
4. Hypertension Urgency vs Emergency
Q1: What is the fundamental clinical difference between hypertensive urgency and hypertensive emergency?
* Answer: Both involve severe elevations in blood pressure (usually Systolic ≥ 180 mmHg and/or Diastolic ≥ 120 mmHg). However, a hypertensive emergency features evidence of acute, progressive target-organ damage (e.g., encephalopathy, MI, aortic dissection, acute pulmonary edema, acute renal failure), whereas hypertensive urgency does not.
Q2: What is the general goal and rate of blood pressure reduction in a hypertensive emergency?
* Answer: Blood pressure should be reduced safely and gradually: lower the Mean Arterial Pressure (MAP) by no more than 25% within the first hour, then target a goal of 160/100–110 mmHg over the next 2–6 hours, and normalize over the next 24–48 hours. Reducing it too fast can compromise cerebral and coronary perfusion.
Q3: What are the two major exceptions to the gradual BP reduction rule in hypertensive emergencies?
* Answer:
* Acute Aortic Dissection: Requires rapid reduction of systolic BP to < 120 mmHg and heart rate to < 60 bpm within 20–30 minutes.
* Acute Ischemic Stroke: BP is permitted to stay higher (up to < 220/120 mmHg if not receiving tPA, or < 185/110 mmHg if a tPA candidate) to maintain collateral perfusion to the ischemic penumbra.
Q4: Which preferred intravenous medications are utilized to manage hypertensive emergencies?
* Answer: Titratable intravenous continuous infusions are preferred, such as Labetalol (dual alpha/beta-blocker), Nicardipine or Clevidipine (dihydropyridine calcium channel blockers), or Nitroprusside (vasodilator).
Q5: How should asymptomatic hypertensive urgency be managed?
* Answer: It does not require intravenous medications or immediate ED admission. It is managed by reinstating or adjusting oral antihypertensive medications and ensuring close outpatient follow-up over 24–48 hours to lower blood pressure gradually.
5. Electrolyte Imbalances
Q1: What is the first-line therapeutic step when managing severe hyperkalemia associated with ECG changes?
* Answer: Immediate administration of intravenous Calcium Gluconate (or Calcium Chloride). Calcium does not lower serum potassium levels; instead, it stabilizes the cardiac myocyte membrane to prevent lethal ventricular arrhythmias.
Q2: What neurological complication can occur if chronic severe hyponatremia is corrected too rapidly?
* Answer: Osmotic Demyelination Syndrome (ODS), historically termed Central Pontine Myelinolysis. To prevent this irreversible condition, serum sodium correction should generally not exceed 8–10 mEq/L within any 24-hour window.
Q3: What are the classic ECG findings associated with severe hypokalemia?
* Answer: Key changes include flattening or inversion of T waves, ST-segment depression, and the appearance of prominent U waves (most visible in precordial leads).
Q4: How do you clinically manage a patient with symptomatic hypocalcemia?
* Answer: Symptomatic hypocalcemia (tetany, seizures, prolonged QT interval, positive Chvostek's/Trousseau's signs) requires intravenous Calcium Gluconate. Concurrently, magnesium levels should be checked and repleted, as hypomagnesemia can cause refractory hypocalcemia.
Q5: What are the common clinical signs of hypermagnesemia, and what is its main etiology?
* Answer: Hypermagnesemia is most commonly caused by advanced renal failure combined with magnesium-containing antacids or laxatives. Clinical signs include a loss of deep tendon reflexes, bradycardia, hypotension, respiratory depression, and cardiac arrest at very high levels.
6. Sepsis
Q1: What are the current Sepsis-3 definitions for Sepsis and Septic Shock?
* Answer:
* Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection, objectively quantified by an acute increase of ≥ 2 points on the SOFA (Sequential Organ Failure Assessment) score.
* Septic Shock: A subset of sepsis where underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality, identified by the need for vasopressors to maintain a MAP ≥ 65 mmHg AND a serum lactate > 2 mmol/L despite adequate fluid resuscitation.
Q2: What elements comprise the Surviving Sepsis Campaign's 1-Hour Bundle?
* Answer: The five steps to initiate within 1 hour of recognition are:
1. Measure serum lactate level.
2. Obtain blood cultures prior to antibiotic administration.
3. Administer broad-spectrum antibiotics.
4. Rapidly administer 30 mL/kg crystalloid fluid for hypotension or lactate ≥ 4 mmol/L.
5. Apply vasopressors if the patient is hypotensive during or after fluid resuscitation to maintain MAP ≥ 65 mmHg.
Q3: What is the first-line vasopressor of choice for managing septic shock?
* Answer: Norepinephrine is the first-line vasopressor of choice due to its potent alpha-1 adrenergic vasoconstrictive properties, which effectively raise MAP with less arrhythmogenic potential than dopamine.
Q4: Why is tracking serial serum lactate levels vital in managing sepsis?
* Answer: Lactate serves as a proxy marker for tissue hypoperfusion and anaerobic metabolism. Monitoring serial lactates helps assess the efficacy of resuscitation; a failing lactate clearance is an unfavorable prognostic sign indicating inadequate resuscitation or uncontrolled infection.
Q5: What screening tool is used at the bedside to quickly identify patients outside the ICU at risk for poor outcomes from suspected infection?
* Answer: The qSOFA (quick SOFA) score. It scores 1 point for each of the following: Altered mental status, Systolic BP ≤ 100 mmHg, and Respiratory rate ≥ 22 breaths/min. A score ≥ 2 suggests a high risk of poor clinical outcomes.
7. Tachy-Bradycardia
Q1: What is the decisive factor when managing any patient presenting with an acute tachyarrhythmia or bradyarrhythmia?
* Answer: Evaluating hemodynamic stability. If the patient is unstable (showing signs of altered mental status, ongoing chest pain, hypotension, or acute heart failure due to the arrhythmia), immediate intervention is mandatory: synchronized cardioversion for tachyarrhythmias, or atropine/transcutaneous pacing for bradyarrhythmias.
Q2: What is the first-line pharmacological treatment for symptomatic bradycardia, and what is its mechanism?
* Answer: Atropine (1 mg IV, repeatable up to a maximum of 3 mg). It works as an anticholinergic/antimuscarinic agent that blocks vagal tone on the sinoatrial (SA) and atrioventricular (AV) nodes, thereby increasing the heart rate.
Q3: How do you differentiate between Mobitz Type I (Wenckebach) and Mobitz Type II second-degree AV blocks on an ECG?
* Answer:
* Mobitz Type I: Features a progressive, step-by-step prolongation of the PR interval until a QRS complex is dropped ("longer, longer, longer, drop, now you have a Wenckebach").
* Mobitz Type II: Features a constant PR interval with intermittent, unexpected dropped QRS complexes. It indicates infra-nodal conduction disease and carries a high risk of progressing to complete heart block.
Q4: What are the two primary management arms for stable Atrial Fibrillation with Rapid Ventricular Response (RVR)?
* Answer:
* Rate Control: Using Beta-blockers (e.g., metoprolol) or Non-dihydropyridine Calcium Channel Blockers (e.g., diltiazem) to slow AV node conduction.
* Rhythm Control: Using antiarrhythmics (e.g., amiodarone, flecainide) or electrical cardioversion to restore sinus rhythm. Long-term stroke risk must also be addressed using the CHA₂DS₂-VASc scoring system to guide anticoagulation.
Q5: What is the definitive treatment for a patient with symptomatic third-degree (complete) heart block?
* Answer: Implantation of a permanent pacemaker. While preparing for definitive placement, the patient must be stabilized using transcutaneous or transvenous temporary pacing.
8. Anemia
Q1: How do you initially classify anemias based on lab evaluations?
* Answer: Classification is guided by the Mean Corpuscular Volume (MCV):
* Microcytic: MCV < 80 fL (e.g., Iron deficiency, Thalassemia, Anemia of chronic disease).
* Normocytic: MCV 80–100 fL (e.g., Acute blood loss, Hemolysis, Chronic kidney disease).
* Macrocytic: MCV > 100 fL (e.g., Vitamin B12 or Folate deficiency, Liver disease, Hypothyroidism).
Q2: How do you differentiate Iron Deficiency Anemia (IDA) from Anemia of Chronic Disease (ACD) using a serum iron panel?
* Answer:
* IDA: Low serum iron, low ferritin (reflecting depleted iron stores), and elevated Total Iron Binding Capacity (TIBC).
* ACD: Low serum iron, normal-to-elevated ferritin (acting as an acute-phase reactant trapped in stores), and low-to-normal TIBC.
Q3: What are the hallmark findings on a peripheral blood smear for Megaloblastic Anemia?
* Answer: The presence of hypersegmented neutrophils (defined as neutrophils with ≥ 6 lobes or ≥ 5% with 5 lobes) alongside large oval-shaped red blood cells (macro-ovalocytes).
Q4: Which laboratory markers indicate hemolytic anemia?
* Answer: Laboratory indicators of active hemolysis include an elevated reticulocyte count, elevated indirect bilirubin, elevated Lactate Dehydrogenase (LDH), and significantly decreased haptoglobin levels (due to haptoglobin binding free hemoglobin).
Q5: What is the standard trigger threshold for a Packed Red Blood Cell (PRBC) transfusion in a stable, hospitalized patient?
* Answer: A restrictive transfusion strategy is recommended, triggering a transfusion when the Hemoglobin drops below 7 g/dL, with a target goal of 7–8 g/dL. Exceptions apply for patients with active acute coronary syndrome or severe symptomatic hemorrhage, where a threshold of < 8 g/dL or higher may be targeted.
9. Myocardial Infarction (MI) / Chest Pain
Q1: What ECG criteria differentiate a STEMI from an NSTEMI?
* Answer: A STEMI is diagnosed by new, convex ST-segment elevations in ≥ 2 anatomically contiguous leads (≥ 1 mm in all leads except V2-V3, where specific age/sex cutoffs apply) or a new left bundle branch block (LBBB) in a symptomatic patient. An NSTEMI lacks acute ST elevations, presenting instead with ST-segment depressions, T-wave inversions, or non-specific changes, paired with elevated cardiac biomarkers.
Q2: What is the immediate standard emergency medical management for a patient with suspected Acute Coronary Syndrome (ACS)?
* Answer: Often summarized by the mnemonic MONA-B:
* Morphine (for refractory pain).
* Oxygen (only if SpO₂ < 90% or patient is in respiratory distress).
* Nitroglycerin (sublingual or IV for chest pain, contraindicated if right ventricular MI or recent PDE-5 inhibitor use).
* Aspirin (162–325 mg chewed immediately).
* Beta-blocker (orally within 24 hours if no signs of heart failure or cardiogenic shock).
Q3: What are the target reperfusion timelines for a patient presenting with an acute STEMI?
* Answer:
* Primary Percutaneous Coronary Intervention (PCI): Door-to-balloon time within 90 minutes at a PCI-capable facility (or within 120 minutes if transfer is required).
* Fibrinolytic Therapy: Door-to-needle time within 30 minutes if PCI cannot be performed within the 120-minute window and there are no contraindications.
Q4: Which cardiac biomarker is preferred for diagnosing myocardial necrosis, and what is its typical release kinetic profile?
* Answer: Cardiac Troponin (I or T) is the preferred biomarker due to its high sensitivity and cardiac specificity. Troponin levels rise within 3–4 hours of myocardial injury, peak at 18–24 hours, and can remain elevated for up to 10–14 days.
Q5: Name two severe mechanical complications that can occur 3 to 14 days following an acute transmural myocardial infarction.
* Answer:
1. Papillary Muscle Rupture: Leads to acute, severe mitral regurgitation and sudden pulmonary edema.
2. Ventricular Free Wall Rupture: Leads to hemopericardium, cardiac tamponade, and sudden pulseless electrical activity (PEA) arrest.
3. Interventricular Septal Rupture: Leads to an acute ventricular septal defect (VSD) with a new holosystolic murmur and right heart failure.
10. COPD/Asthma
Q1: How do you differentiate Asthma from COPD on pulmonary function tests (PFTs)?
* Answer: While both demonstrate an obstructive pattern (FEV1/FVC ratio < 0.70), Asthma shows significant reversibility post-bronchodilator administration, defined as an increase in FEV1 of > 12% and > 200 mL. COPD exhibits fixed, non-reversible or poorly reversible airflow limitation after a bronchodilator.
Q2: What is the cornerstone long-term maintenance drug class for persistent Asthma compared to COPD?
* Answer: For Asthma, the foundational maintenance treatment is an Inhaled Corticosteroid (ICS) to control chronic eosinophilic airway inflammation. For COPD, maintenance focuses on long-acting bronchodilators: LAMAs (Long-Acting Muscarinic Antagonists) and/or LABAs (Long-Acting Beta-Agonists), reserving ICS only for patients with high blood eosinophils or frequent exacerbations.
Q3: What are the four core pillars of managing an acute COPD exacerbation in the hospital?
* Answer:
1. Oxygen Therapy: Titrated carefully to a target SpO₂ of 88–92% to prevent hypercapnic respiratory drive suppression.
2. Short-Acting Bronchodilators: Scheduled or PRN inhaled SABAs (albuterol) and SAMAs (ipratropium).
3. Systemic Corticosteroids: Oral or IV glucocorticoids (e.g., prednisone 40 mg for 5 days) to reduce airway inflammation.
4. Antibiotics: Given if the patient presents with increased sputum purulence plus increased volume or dyspnea, or requires mechanical ventilation.
Q4: What clinical sign on physical examination and finding on arterial blood gas (ABG) indicates impending respiratory failure during a severe asthma attack?
* Answer: On examination, a "silent chest" (absence of wheezing due to minimal air movement) is a critical warning sign. On an ABG, a normal or elevated pCO₂ is ominous; hyperventilation should normally cause a low pCO₂, so a rising pCO₂ indicates respiratory muscle fatigue and impending failure.
Q5: Which interventions have been shown to definitively prolong survival in patients with advanced COPD?
* Answer:
* Smoking cessation (the most effective intervention to slow FEV1 decline).
* Long-Term Oxygen Therapy (LTOT) in patients meeting criteria for chronic resting hypoxemia (PaO₂ ≤ 55 mmHg or SpO₂ ≤ 88%).
* Lung volume reduction surgery in highly selected patient subsets.
11. Pancreatitis / Cholecystitis / Appendicitis
Q1: What are the three diagnostic criteria for acute pancreatitis, and how many are required for a diagnosis?
* Answer: A diagnosis requires meeting at least 2 out of the following 3 criteria:
1. Acute, severe epigastric pain that frequently radiates to the back.
2. Serum lipase or amylase levels elevated to ≥ 3 times the upper limit of normal.
3. Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging (contrast-enhanced CT, MRI, or transabdominal ultrasound).
Q2: Describe and differentiate Murphy's sign, McBurney's point tenderness, and Rovsing's sign.
* Answer:
* Murphy's Sign: Cessation of inspiration during deep palpation of the right upper quadrant; indicates acute cholecystitis.
* McBurney's Point Tenderness: Maximal tenderness located one-third of the distance from the anterior superior iliac spine to the umbilicus; indicates acute appendicitis.
* Rovsing's Sign: Palpation of the left lower quadrant elicits pain in the right lower quadrant; indicates focal peritoneal irritation from acute appendicitis.
Q3: What is the preferred initial imaging study for suspected acute cholecystitis, and what findings support the diagnosis?
* Answer: A Right Upper Quadrant (RUQ) abdominal ultrasound. Key diagnostic findings include gallstones, gallbladder wall thickening (> 3 mm), pericholecystic fluid, and a sonographic Murphy's sign.
Q4: What is the primary management strategy for the first 24–48 hours of acute pancreatitis, and what parameters guide its success?
* Answer: Early, aggressive intravenous fluid resuscitation (preferably with Lactated Ringer's). Fluid resuscitation effectiveness is tracked by monitoring urine output (> 0.5–1 mL/kg/hr), stabilizing heart rate and blood pressure, and watching for a downward trend in Hematocrit and BUN levels.
Q5: What are the classic complications of an untreated or delayed presentation of acute appendicitis?
* Answer: Appendiceal perforation leading to localized periappendiceal abscess formation, generalized peritonitis, pylephlebitis (septic portal vein thrombosis), and systemic sepsis.
12. Heart Failure
Q1: How do you classify Heart Failure based on left ventricular ejection fraction (LVEF)?
* Answer:
* HFrEF (Heart Failure with Reduced Ejection Fraction): LVEF ≤ 40%.
* HFmrEF (Heart Failure with Mildly Reduced Ejection Fraction): LVEF 41–49%.
* HFpEF (Heart Failure with Preserved Ejection Fraction): LVEF ≥ 50%.
Q2: What four drug classes constitute Guideline-Directed Medical Therapy (GDMT) to improve survival in patients with HFrEF?
* Answer: The "four pillars" of survival-prolonging GDMT are:
1. ARNI (Angiotensin Receptor-Neprilysin Inhibitor, e.g., sacubitril/valsartan) preferred over ACE inhibitors or ARBs.
2. Evidence-based Beta-blockers (Carvedilol, Metoprolol Succinate, or Bisoprolol).
3. MRAs (Mineralocorticoid Receptor Antagonists, e.g., spironolactone or eplerenone).
4. SGLT2 inhibitors (e.g., empagliflozin or dapagliflozin).
Q3: How do the clinical signs and symptoms of isolated Left-Sided Heart Failure differ from Right-Sided Heart Failure?
* Answer:
* Left-Sided HF: Predominantly causes signs of pulmonary congestion due to fluid backing up into the lungs: dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea (PND), and pulmonary crackles/rales.
* Right-Sided HF: Predominantly causes signs of systemic venous congestion: Jugular Venous Distension (JVD), hepatojugular reflux, hepatomegaly, ascites, and symmetric dependent peripheral edema.
Q4: What is the primary diagnostic utility of B-type Natriuretic Peptide (BNP) or NT-proBNP in a patient presenting with acute dyspnea?
* Answer: These biomarkers possess a very high negative predictive value. A normal or low BNP (< 100 pg/mL) or NT-proBNP (< 300 pg/mL) rules out acute decompensated heart failure as the cause of dyspnea with high confidence.
Q5: What is the first-line therapeutic approach for managing an Acute Decompensated Heart Failure (ADHF) exacerbation with volume overload?
* Answer: Intravenous administration of loop diuretics (e.g., IV furosemide or bumetanide), usually initiated at 1–2.5 times the patient's home total daily oral dose. Clinicians must closely track hourly urine output, daily weights, and serum potassium/kidney function.
13. Pyelonephritis
Q1: What clinical presentation differentiates acute pyelonephritis from an uncomplicated lower urinary tract infection (Cystitis)?
* Answer: While both feature lower urinary tract symptoms (dysuria, frequency, urgency), acute pyelonephritis involves systemic infection and upper tract inflammation, presenting with high fevers, chills, flank pain, nausea, vomiting, and Costovertebral Angle (CVA) tenderness.
Q2: What baseline laboratory evaluations are required when managing a patient with suspected pyelonephritis?
* Answer: A Urinalysis (showing pyuria, positive leukocyte esterase, nitrites, and WBC casts) paired with a Urine Culture and Susceptibility test. In hospitalized or septic patients, Complete Blood Count (CBC), Basic Metabolic Panel (BMP to check renal function), and blood cultures are also required.
Q3: What are the preferred empirical oral antibiotic options for treating uncomplicated outpatient pyelonephritis?
* Answer: Oral Fluoroquinolones such as Ciprofloxacin (500 mg twice daily for 7 days) or Levofloxacin (750 mg once daily for 5 days) are preferred first-line empirical agents, provided local resistance rates do not exceed 10%. Alternatively, an initial long-acting parenteral dose of Ceftriaxone (1 g IV) followed by oral Trimethoprim-Sulfamethoxazole or a Beta-lactam can be used.
Q4: When is renal imaging (CT scan or Ultrasound) indicated for a patient diagnosed with pyelonephritis?
* Answer: Imaging is not routinely required for simple, responsive pyelonephritis. It is indicated if the patient fails to improve clinically after 48–72 hours of appropriate antibiotic therapy, has suspected urinary tract obstruction, history of nephrolithiasis, recurrent episodes, or is unstable/septic (to look for complications like a renal/perinephric abscess).
Q5: What are the potentially life-threatening complications of severe or improperly treated acute pyelonephritis?
* Answer: Systemic bacteremia and septic shock, perinephric or intrarenal abscess formation, renal papillary necrosis, emphysematous pyelonephritis (especially in diabetic patients), and chronic renal scarring or acute kidney injury (AKI).